Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Provides Update on Phase II Bladder Cancer Study

Accesswire May 10, 2023

Theralase® Releases FY2022 Audited Financial Statements

GlobeNewswire April 26, 2023

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

GlobeNewswire February 23, 2023

Anatomy of a Flagship Asset: Theralase Technologies' (TSXV:TLT) Anti-Cancer Therapy

Trevor Abes  February 22, 2023

Theralase® Awarded TSX Venture 50(TM) Recognition as a Top Performing Company

GlobeNewswire February 21, 2023

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

GlobeNewswire February 2, 2023

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

GlobeNewswire January 25, 2023

Theralase ® Announces Warrant Extension

GlobeNewswire January 5, 2023

Theralase Releases Q322 Interim Financial Statements

GlobeNewswire November 29, 2022

Theralase (TSXV:TLT) grants stock options

Brieanna McCutcheon  November 21, 2022

Theralase® Grants Stock Options

GlobeNewswire November 21, 2022

Theralase Technologies (TSXV:TLT) closes private placement

John Ballem  November 18, 2022

Theralase ® Closes Private Placement Equity Financing

GlobeNewswire November 17, 2022

Theralase (TSXV:TLT) commences C$2.5M follow-on private placement equity financing

Azuka Onwuka October 3, 2022

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

GlobeNewswire October 3, 2022

Theralase® Announces Warrant Extension

GlobeNewswire September 29, 2022

Theralase (TSXV:TLT) closes $2.5M private placement

John Ballem  September 23, 2022

Theralase® Closes $2.5M Private Placement Equity Financing

GlobeNewswire September 22, 2022

Theralase Releases Q222 Interim Financial Statements

GlobeNewswire August 29, 2022

Theralase (TSXV:TLT) granted Brazilian patent

Trevor Abes  June 28, 2022